182 publications
Name | Date | Type | Actions |
---|---|---|---|
Pierre Konareff est nommé Directeur Financier et Juridique du Groupe Vétoquinol (french) Vétoquinol annonce la nomination de Pierre Konareff au poste de Directeur Financier et Juridique du groupe. |
Public releases | ||
Vétoquinol strengthens its presence in Canada in the compagnion animal market Vétoquinol announces the acquisition of the animal health business assets of VETCOM 1979 INC. The animal health business of VETCOM 1979 INC. includes annual revenue of around CAD1.5 million. The company covers nearly 65% of the market for ophthalmological unguents in Canada. |
Public releases | ||
Satisfactory revenue growth for 1st quarter 2008: +4.6% on a constant basis Revenue for the first quarter of 2008 reached €54.7 M, an increase of 3.0% over the first quarter of 2007, a high revenue growth period. First quarter 2008 growth was particularly significant for the livestock segment. |
Public releases | ||
Earnings for 2007 attest to strength of business growth model The Vétoquinol board of directors, meeting on February 22, 2008, reviewed the group’s business in 2007 and approved the related financial statements. In 2007, Vétoquinol once again achieved significant improvement in its key performance |
Public releases | ||
VÉTOQUINOL S.A. and JUROX PTY LTD extend their collaboration on ALFAXAN® in Europe |
Public releases | ||
KIBOW BIOTECH INC. et Vétoquinol S.A. étendent leur accord de commercialisation et de licence vétérinaire pour des applications mondiales (french) |
Public releases | ||
Revenue grows by 10.3% in 2007, to €233.4 M |
Public releases | ||
Vétoquinol announces opening of its first decentralized R&D center in Canada |
Public releases | ||
Vétoquinol to market and distribute Vetprofen in the United States |
Public releases | ||
3rd quarter revenues confirm promise of For the nine months ended September 30, 2007, Vétoquinol’s total revenues reached €166.0 M, an increase of 11.3% compared with the |
Public releases |